Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/10/23
End: 11/15/24
Due: 11/15/25
Phase: N/A
Priority: Normal
Start: 03/28/23
End: 07/15/25
Due: 07/15/26
Phase: N/A
Priority: Normal
Start: 03/15/24
End: 07/15/25
Due: 07/15/26
Phase: N/A
Priority: Normal
Start: 11/04/24
End: 10/15/25
Due: 10/15/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers | NCT05817643 | Allyx Therapeutics | user2@example.com | None | 2023-01-10 | 2024-11-15 | 2025-11-15 | - | - | 2025-07-14 |
| A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease | NCT05804383 | Allyx Therapeutics | user2@example.com | None | 2023-03-28 | 2025-07-15 | 2026-07-15 | - | - | 2025-07-14 |
| A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's | NCT06309147 | Allyx Therapeutics | user2@example.com | None | 2024-03-15 | 2025-07-15 | 2026-07-15 | - | - | 2025-07-14 |
| A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates | NCT06632990 | Allyx Therapeutics | user2@example.com | None | 2024-11-04 | 2025-10-15 | 2026-10-15 | - | - | 2025-07-14 |